RenovoRx, Inc. (NASDAQ:RNXT) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC lessened its holdings in RenovoRx, Inc. (NASDAQ:RNXT) by 37.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 197,250 shares of the company’s stock after selling 117,942 shares during the period. ADAR1 Capital Management LLC owned about 0.82% of RenovoRx worth $254,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC raised its position in RenovoRx by 61.9% in the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company’s stock valued at $247,000 after purchasing an additional 89,018 shares during the period. Institutional investors and hedge funds own 3.10% of the company’s stock.

RenovoRx Trading Down 10.4 %

RNXT opened at $0.79 on Tuesday. RenovoRx, Inc. has a twelve month low of $0.75 and a twelve month high of $1.69. The firm has a market cap of $18.96 million, a price-to-earnings ratio of -1.39 and a beta of 1.12. The company has a fifty day simple moving average of $1.06 and a 200 day simple moving average of $1.14.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts forecast that RenovoRx, Inc. will post -0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RNXT shares. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of RenovoRx in a research report on Friday. Ascendiant Capital Markets boosted their price target on RenovoRx from $8.25 to $9.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.